Exousia Bio, Inc. completed an acquisition involving Exousia Ai, Inc. for 62,223,000 shares of Company common stock (closed 2025-11-17).
“of the issued and outstanding capital stock of Exousia Ai, with Exousia Ai becoming the Company’s wholly-owned subsidiary, in consideration of the Company’s issuing a total of 62,223,000 shares of Company common stock (the “Acquisition Shares” ) to the shareholders of Exousia Ai. On November 17, 2025, the parties closed the Reorganization Agreement, such that”
M&A Transactions
Exousia Bio, Inc. underwent a change of control involving Zhang Shengwu for $335,910 in cash (closed 2024-12-06).
“of the outstanding shares of the Company’s common stock and constitute voting control of the Company. The total consideration paid by Mr. Shengwu for the Acquired Shares was $335,910 in cash, $318,410 to Mr. Witmer and $17,500 to Mr. Townsend. In conjunction with the Change-in-Control Agreements, on December 6, 2024, Dwight Witmer resigned as a Director, CEO,”
Stephen Edward Townsend was appointed as Chief Operating Officer at Exousia Bio, Inc..
“On March 15, 2023, the board of directors (the “Board”) of LAMY (the “Company”) appointed Mr. Stephen Edward Townsend, to the Board as Chief Operating Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.